Table 2.

The outcomes of ovarian stimulation in quinagolide and cabergoline-treated groups

Variable	Quinagolide n=63	Cabergoline n=63	Effect (95% CI)	P value
E2 on day of GnRH agonist (pg/ml)	3293.74 ± 3836.9	3615.79 ± 1473.5	0.11 (-0.24-0.46)	0.304
HB (g/dl)	12.10 ± 1.42	12.61 ± 1.17	-0.39 (-0.74-0.04)	0.034
HCT	36.85 ± 4.38	38.37 ± 3.77	-0.37 (-0.72-0.02)	0.045
Number of oocytes retrieval	29.02 ± 11.45	28.76 ± 6.46	0.03 (-0.32-0.38)	0.443
Number of GV	4.02 ± 2.93	3.60 ± 2.38	0.16 (-0.19-0.51)	0.834
Number of MI	2.81 ± 1.92	3.49 ± 2.15	-0.33 (-0.68-0.02)	0.786
Number of MII	22.58 ± 9.57	22.05 ± 7.88	0.06 (-0.29-0.41)	0.386
Number of embryo	6.22 ± 15.00	5.59 ± 17.23	-0.38 (-0.73-0.02)	0.037
Number of high quality of embryos	18.3 ± 5.1	14 ± 8.6	0.61 (0.25-0.96)	0.001
OHSS	14 (22.2)	30 (47.6)	0.46 (0.27-0.79)	0.001
Mild	6 (9.5)	9 (14.28)	0.66 (0.25-1.76)	0.432
Moderate	6 (9.5)	11 (17.46)	0.54 (0.22-1.38)	0.545
Severe	2 (3.1)	10 (15.8)	0.2 (0.04-0.87)	0.001
GI symptoms	38 (59.4)	40 (63.5)	0.95 (0.72-1.25)	0.857
Ascites	14 (21.9)	39 (61.9)	0.36 (0.22-0.59)	0.0001
Paracentesis	7 (10.9)	17 (27.0)	0.41 (0.18-0.92)	0.021
Admission	2 (3.1)	14 (22.2)	0.14 (0.03-0.60)	0.001

Data are presented as mean + SD or n (%). E2; Estradiol, GnRH; Gonadotropin releasing hormone, HB; Hemoglobin, HCT; Hematocrit, GV; Germinal vesicle, MI; Metaphase I, MII; Metaphase II, OHSS; Ovarian hyper stimulation syndrome, GI; Gastrointestinal, and CI; Confidence interval.l.